Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/128321
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Karnes, J.H. | - |
dc.contributor.author | Rettie, A.E. | - |
dc.contributor.author | Somogyi, A.A. | - |
dc.contributor.author | Huddart, R. | - |
dc.contributor.author | Fohner, A.E. | - |
dc.contributor.author | Formea, C.M. | - |
dc.contributor.author | Lee, M.T.M. | - |
dc.contributor.author | Llerena, A. | - |
dc.contributor.author | Whirl-Carrillo, M. | - |
dc.contributor.author | Klein, T.E. | - |
dc.contributor.author | Phillips, E.J. | - |
dc.contributor.author | Mintzer, S. | - |
dc.contributor.author | Gaedigk, A. | - |
dc.contributor.author | Caudle, K.E. | - |
dc.contributor.author | Callaghan, J.T. | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Clinical Pharmacology and Therapeutics, 2021; 109(2):302-309 | - |
dc.identifier.issn | 0009-9236 | - |
dc.identifier.issn | 1532-6535 | - |
dc.identifier.uri | http://hdl.handle.net/2440/128321 | - |
dc.description | First published: 11 August 2020 | - |
dc.description.abstract | Phenytoin is an antiepileptic drug with a narrow therapeutic index and large inter-patient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org). | - |
dc.description.statementofresponsibility | Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi, Rachel Huddart, Alison E. Fohner, Christine M. Formea ... et al. | - |
dc.language.iso | en | - |
dc.publisher | American Society for Clinical Pharmacology and Therapeutics | - |
dc.rights | © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics | - |
dc.source.uri | http://dx.doi.org/10.1002/cpt.2008 | - |
dc.subject | CPIC | - |
dc.subject | CYP2C9 | - |
dc.subject | HLA-B | - |
dc.subject | Phenytoin | - |
dc.subject | Stevens-Johnson syndrome | - |
dc.subject | fosphenytoin | - |
dc.subject | pharmacogenetics | - |
dc.subject | toxic epidermal necrolysis | - |
dc.title | Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1002/cpt.2008 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1123499 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/108798 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Somogyi, A.A. [0000-0003-4779-0380] | - |
Appears in Collections: | Aurora harvest 4 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.